How NVIDIA is helping to AI-enable the entire healthcare system

AI transformation in healthcare: The U.S. healthcare system is rapidly adopting artificial intelligence technologies across various domains, from research laboratories to clinical settings, to enhance efficiency and drive innovation.

• NVIDIA’s AI Summit in Washington, D.C. showcases the latest AI-accelerated tools, including NVIDIA NIM and NVIDIA NIM Agent Blueprints, which are being deployed in the public sector.
• These technologies are being used to advance medical image analysis, aid in drug discovery, and extract information from complex medical databases.

Key applications in research: National health institutions are leveraging NVIDIA’s AI tools to accelerate critical research processes and improve patient care.

• The National Cancer Institute is utilizing AI models built with NVIDIA MONAI for medical imaging, including the VISTA-3D NIM foundation model for 3D CT image segmentation and annotation.
• The National Center for Advancing Translational Sciences (NCATS) is employing NIM Agent Blueprint for AI-based virtual screening to expedite and reduce costs in drug molecule development.

NIM microservices and Agent Blueprints: NVIDIA offers a range of AI tools and pre-trained models that can be customized and refined based on organizational needs and user feedback.

• These resources are available through ai.nvidia.com and accessible via various cloud service providers and technology solutions providers.
• Developers can access and download dozens of NIM microservices and a growing set of NIM Agent Blueprints for free, with deployment options through the NVIDIA AI Enterprise software platform.

Advancements in drug discovery: New NIM microservices are revolutionizing the drug discovery process by enabling more efficient and cost-effective research methods.

• The AlphaFold2-Multimer NIM microservice allows researchers to predict protein structures from sequences in minutes, reducing the need for time-consuming laboratory tests.
• RFdiffusion NIM microservice uses generative AI to design novel proteins that are likely to bind with target molecules, streamlining the identification of promising drug candidates.

Accelerating data analysis: NVIDIA’s AI tools are helping researchers process and analyze vast amounts of healthcare data more efficiently.

• NCATS is using RAPIDS, a suite of open-source software libraries, to accelerate drug discovery research by mapping chemical reactions across unknown chemical spaces.
• The Genetic and Rare Diseases Information Center is exploring the use of PDF data extraction blueprints to develop generative AI tools for gleaning information from previously unsearchable databases.

Industry collaboration and integration: NVIDIA is partnering with various startups, cloud service providers, and global systems integrators to make its AI technologies more accessible to federal healthcare researchers.

• Abridge, an NVIDIA Inception startup, is working with the U.S. Department of Veterans Affairs to transcribe and summarize clinical appointments using NVIDIA technologies.
• Amazon Web Services is collaborating with NVIDIA to make NIM Agent Blueprints broadly accessible to the biomedical research community through the NIH STRIDES Initiative.
• ConcertAI is integrating NIM microservices and other NVIDIA technologies into its suite of AI solutions for oncology research and clinical care.

Future implications: The widespread adoption of AI in healthcare research and clinical settings has the potential to significantly accelerate medical breakthroughs and improve patient care.

• As these technologies become more integrated into healthcare systems, we can expect to see faster drug discovery processes, more accurate medical imaging analysis, and improved access to critical healthcare information.
• However, it will be crucial to monitor the ethical implications and potential biases in AI-driven healthcare solutions to ensure equitable and responsible implementation.